820 M6A mRNA Demethylase FTO Regulates Tumorigenicity and Response to Anti-Pd-1 Immunotherapy in Melanoma

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.896
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Beyond PD-1 Immunotherapy in Malignant Melanoma

Dermatology and Therapy
Dermatology
2019English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Gut Microbiome Affects the Response to Anti-Pd-1 Immunotherapy in Patients With Hepatocellular Carcinoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

FTO: Linking M6A Demethylation to Adipogenesis

Cell Research
Cell BiologyMolecular Biology
2014English

TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Dynamic Metrics-Based Biomarkers to Predict Responders to Anti-Pd-1 Immunotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy